Lydia Crowe, Director at Mtech Access, shares her experiences of returning to work during lockdown, following her maternity leave. With a background in health economics and medical writing, and more...
Read More
What changes can we expect to pharmacy, medicines management, and specialised commissioning in the new NHS? What will the introduction of medicines registers, as outlined in the Government’s Health and...
Read More
Are you looking to launch a new medical technology, medical or diagnostic device in the UK, Europe or North America? Would you like to know how health economic modelling could...
Read More
In this four-part series, we explore the various challenges facing orphan medicines entering the European market and suggest solutions that can help improve patient access. In the final part of...
Read More
Are you wondering what integrated care will look like when the Health and Care White Paper proposals become a reality? Few are better placed than Dr John Ribchester to inform...
Read More
On 5th February 2021, the UK Government's draft Health and Care White Paper was leaked online. An authorised version was later published on 11th February 2021. The White Paper sets...
Read More
Challenges for orphan medicines entering the European market – Part 3: Economic evidence development
In this four-part series, we explore the various challenges facing orphan medicines entering the European market and suggest solutions that can help improve patient access. In Part 3 of the...
Read More
Challenges for orphan medicines entering the European market – Part 2: Clinical evidence development
In this four-part series, we explore the various challenges facing orphan medicines entering the European market and suggest solutions that can help improve patient access. In Part 2 of the...
Read More
Calum Jones, Consultant Health Economist at Mtech Access, shares his passion for helping MedTech firms build health economic models that help their innovative new technologies reach patients. Tell us about...
Read More
In this four-part series, we explore the various challenges facing orphan medicines entering the European market and suggest solutions that can help improve patient access. In Part 1, we explore...
Read More
